By Richard C. Holcomb, M.D., F.A.C.S., Captain, Medical Corps, U. S. Navy, Retired. With Introduction by C. S. Butler, A.B., M.D., Li.D., Rear Admiral, Medical Corps, U. S. Navy. Pp. 1-189. Froben Press. New York. 1937
The therapeutic efficacy of CP-46,665-1, a synthetic lipoidal amine with proven immunomodulatory and anti-tumor properties, in combination with chemotherapy was evaluated in L. donovani-infected C57Bl/6 mice. Immunostimulation and drug treatment resulted in a 10-fold lesser infection level than in untreated mice, while animals treated with Glucantime® alone exhibited only a modest amelioration of the infection. We also studied the capacity of CP-elicited peritoneal macrophages of C57Bl/6 mice cultured alone or in combination with Glucantime® and/or lymphokine to eliminate intracellular L. donovani amastigotes. When CP-elicited cells were incubated with Glucantime®, they exhibited a significantly higher killing potential than did drug treated thioglycollate-elicited cells. CP-macrophages stimulated with lymphokine alone or in combination with antimonial drug, killed amastigotes more rapidly and efficiently than similarly treated thioglycollate-elicited macrophages. In vivo and in vitro results of this study show that a combined regimen of immunostimulation with CP and antimonial drug is more effective in treatment of L. donovani infection than either treatment alone.
Permanent address: Clinica Malattie Tropicali e Subtropicali, Ia Facolta' di Medicina e Chirurgia, Universita' di Napoli, Via Cotugno, 1, 80135 Napoli, Italia.